Woodline Partners’s CASI Pharmaceuticals CASI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-133,406
Closed -$113K 1045
2025
Q4
$113K Sell
133,406
-32,234
-19% -$41.7K ﹤0.01% 1009
2025
Q3
$275K Hold
165,640
﹤0.01% 858
2025
Q2
$195K Buy
165,640
+1,275
+0.8% +$2.34K ﹤0.01% 904
2025
Q1
$355K Buy
164,365
+64,675
+65% +$158K ﹤0.01% 849
2024
Q4
$282K Buy
99,690
+69,158
+227% +$328K ﹤0.01% 893
2024
Q3
$188K Buy
+30,532
New +$197K ﹤0.01% 578

Other funds holding CASI

Woodline Partners's CASI Position: Q1 2026 in Review

Woodline Partners sold out of CASI Pharmaceuticals (CASI) in Q1 2026, closing a stake of 133,406 shares — an estimated $113K sold.

Woodline Partners first reported a position in CASI in Q3 2024 and held it in 6 quarters. The position peaked at $355K in Q1 2025. 1 fund tracked by Wall St. Rank holds CASI as of Q1 2026.

  • Woodline Partners reported no remaining CASI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Woodline Partners sold 133,406 CASI Pharmaceuticals shares in Q1 2026, an estimated $113K.
  • Woodline Partners first reported a position in CASI Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Woodline Partners's CASI Pharmaceuticals position peaked at $355K in Q1 2025.
  • 1 fund tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.